Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iconovo ABOSTO:ICO -1.20%33 EV-to-OCF is -2.68 as of Aug. 30, 2026. GuruFocus rates OSTO:ICO with a GF Score™ of 33/100 and a GF Value™ of kr0.34 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Iconovo AB ranks better than 68.9% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Iconovo AB's Enterprise Value is kr86.45 Mil.
Iconovo AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr-32.28 Mil. Therefore, Iconovo AB's EV-to-OCF for today is -2.68.
The historical rank and industry rank for Iconovo AB's EV-to-OCF or its related term are showing as below:
OSTO:ICO'
s EV-to-OCF Range Over the Past 10 Years
Min: -224.33 Med: -13.57 Max: 173.78
Current: -2.68
During the past 10 years, the highest EV-to-OCF of Iconovo AB was 173.78. The lowest was -224.33. And the median was -13.57.
OSTO:ICO's EV-to-OCF is ranked better than 68.9% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.88
vs OSTO:ICO: -2.68
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Iconovo AB's share price for today is kr1.24.
Iconovo AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.610.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Iconovo AB EV-to-OCF Related Terms
Iconovo AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Iconovo AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Iconovo AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iconovo AB EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Iconovo AB's EV-to-OCF falls into.
Iconovo AB's current Enterprise Value is kr86.45 Mil.
Iconovo AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-32.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iconovo AB (OSTO:ICO) has a EV-to-OCF of -2.68 as of Aug. 30, 2026. According to the industry distribution chart, Iconovo AB ranks #265 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 31.1%.
Is Iconovo AB's EV-to-OCF too high?
Iconovo AB's current EV-to-OCF is -2.68. Based on the distribution chart, Iconovo AB ranks #265 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Iconovo AB has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Iconovo AB ranks #265 out of 852 companies for EV-to-OCF. This puts Iconovo AB in the upper half of its industry. The industry median EV-to-OCF is 7.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.88, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iconovo AB's current EV-to-OCF is -2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.34, compared to a current price of kr1.24 — trading 264.7% above its estimated fair value. The current EV-to-OCF is -2.68. Iconovo AB's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current EV-to-OCF is -2.68 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iconovo AB (OSTO:ICO) Overvalued in 2026?
Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued.
The current stock price of kr1.24 is trading 264.7% above its estimated GF Value™ of kr0.34.
GuruFocus considers Iconovo AB to be Significantly Overvalued.
Key valuation signals for OSTO:ICO:
EV-to-OCF: -2.68
GF Value™: kr0.34 vs. price of kr1.24 (264.7% above fair value)
No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
33GF Score
Get the complete analysis for OSTO:ICO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ICO has been successfully added to your 
